Table 1 Clinical trials using novel drugs that target CSCs
From: Unveiling the mechanisms and challenges of cancer drug resistance
Drug Name | Experimental study | Type of Cancer | Clinical Phase | Reference |
|---|---|---|---|---|
Sonidegib (LDE225) | LDE225 has the potential to disrupt CSC niches and overcome docetaxel resistance | TNBC | 1b | [112] |
RO4929097 | CSC-mediated antiandrogen resistance, tamoxifen resistance, and radiation resistance are reversed | Recurrent Malignant Glioma | 1 | [113] |
PF-03084014 | Counteracting docetaxel resistance in CSC | Desmoid Fibromatosis | 1 | [114] |
PRI-724 | It could overcome cisplatin resistance in CSCs and reduce the expression of SOX2 and CD44 | Hepatitis C Virus-related Cirrhosis | 1 | [115] |
Vismodegib (GDC-0449) | It has the potential to overcome radiation, carboplatin/erlotinib resistance as well as stemness | Multiple basal-cell carcinomas (MIKIE) | 2 | [116] |